ReviewCold Spring Harbor perspectives in medicine2011
Infantile hemangioma-mechanism(s) of drug action on a vascular tumor.
Review in Cold Spring Harbor perspectives in medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- The effectiveness and safety of topical β-receptor blocker in treating superficial infantile haemangiomas: A meta-analysis including 20 studies.British journal of clinical pharmacology · 2020Pooled it
- Infantile hemangiomas and retinopathy of prematurity: clues to the regulation of vasculogenesis.European journal of pediatrics · 2013Pooled it
- Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.The Journal of clinical investigation · 2015Trial
- Multi-omics unravels multiple pharmacological actions in a murine model of infantile hemangioma receiving oxymatrine therapy.Discover oncology · 2026Article
- Immune microenvironment of infantile hemangioma: cellular dynamics, molecular networks, and emerging immunomodulatory strategies.Frontiers in immunology · 2026Review
- Factors influencing treatment duration of oral propranolol in infantile hemangioma: a five-year retrospective analysis.Frontiers in pediatrics · 2025Article
- Hypoxia-driven angiogenesis and metabolic reprogramming in vascular tumors.Frontiers in cell and developmental biology · 2025Review
- CD26 Is Differentially Expressed throughout the Life Cycle of Infantile Hemangiomas and Characterizes the Proliferative Phase.International journal of molecular sciences · 2024Article
- Use of Propanolol versus Intralesional Bleomycin in the Management of Infantile Hemangioma: A Comparative Study.African journal of paediatric surgery : AJPS · 2023Article
- β-Adrenoreceptors as Therapeutic Targets for Ocular Tumors and Other Eye Diseases-Historical Aspects and Nowadays Understanding.International journal of molecular sciences · 2023Review
- Three-Dimensional Microtumor Formation of Infantile Hemangioma-Derived Endothelial Cells for Mechanistic Exploration and Drug Screening.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Is Infantile Hemangioma a Neuroendocrine Tumor?International journal of molecular sciences · 2022Article
- Update on infantile hemangioma.Clinical and experimental pediatrics · 2021Article
- Infantile Hemangiomas: An Update on Pathogenesis and Treatment.Journal of clinical medicine · 2021Review
- Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Giant Hepatic Hemangioma Regressed Significantly Without Surgical Management: A Case Report and Literature Review.Frontiers in medicine · 2021Article
- Treatment patterns and outcomes in children with infantile hemangiomas: A retrospective observational analysis.SAGE open medicine · 2021Article
- Treatment of Chemotherapy-Induced Subungual Pyogenic Granuloma with Topical Timolol Solution.Skin appendage disorders · 2021Article
- Kasabach-Merritt phenomenon with cellulitis in infant.BMJ case reports · 2020Article
- Treatments for infantile Hemangioma: A systematic review and network meta-analysis.EClinicalMedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infantile hemangioma (IH), a benign vascular tumor, is the most common tumor of infancy, with an incidence of 5%-10% at the end of the first year. The tumor displays a distinctive life cycle consisting of a proliferating phase, occurring in the first months of life, followed by an involuting phase. Thus, IH represents a unique model of postnatal vasculogenesis, angiogenesis, and vessel regression. Traditionally, corticosteroids were the drug of choice when treatment of IH was indicated. In recent years, beta-blockers, most specifically propranolol, have serendipitously been shown to be an effective pharmacological treatment. This article will focus on the mechanism of action of these two drugs, the old and the new treatments, in slowing the growth and accelerating involution of IH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.